圣诺生物
(688117)
| 流通市值：36.48亿 | | | 总市值：36.48亿 |
| 流通股本：1.12亿 | | | 总股本：1.12亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 175,233,865.96 | 218,705,136.59 | 149,557,782.76 | 236,017,824.99 |
| 应收票据及应收账款 | 154,166,280.03 | 102,667,258.27 | 101,684,565.47 | 75,657,422.22 |
| 其中：应收票据 | 960,330.42 | 914,693.39 | 300,000 | 160,000 |
| 应收账款 | 153,205,949.61 | 101,752,564.88 | 101,384,565.47 | 75,497,422.22 |
| 应收款项融资 | 316,840 | 495,891.84 | 1,672,800 | 917,510 |
| 预付款项 | 13,691,652.4 | 12,342,630.49 | 11,062,878.98 | 9,702,348.29 |
| 其他应收款合计 | 5,538,252.35 | 7,972,549.71 | 7,721,020.39 | 8,334,893.48 |
| 存货 | 293,371,482.07 | 304,753,127.04 | 255,721,887.68 | 232,984,639.87 |
| 合同资产 | 19,769,241.01 | 22,034,841.77 | 18,545,768.21 | 10,458,838.18 |
| 其他流动资产 | 35,981,777.83 | 29,078,327.46 | 24,386,373.21 | 24,889,683.21 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 708,094,391.65 | 718,206,763.17 | 651,410,473.7 | 629,667,242.24 |
| 非流动资产: | | | | |
| 长期股权投资 | 21,483,316.51 | 21,189,315.43 | 20,935,092.35 | 21,180,603.5 |
| 其他权益工具投资 | 45,955,932.96 | 58,405,000 | 58,405,000 | 53,405,000 |
| 其他非流动金融资产 | 35,947,648 | 31,447,648 | 31,447,648 | 27,400,000 |
| 投资性房地产 | 1,728,790.15 | 1,783,159.24 | - | - |
| 固定资产 | 376,468,978.46 | 377,616,992.1 | 278,058,852.11 | 271,635,167.69 |
| 在建工程 | 371,232,256.34 | 348,971,162.49 | 302,442,296.11 | 305,091,472.89 |
| 使用权资产 | 604,533.86 | 845,529.23 | 1,086,524.6 | 1,327,519.97 |
| 无形资产 | 55,972,456.1 | 40,195,857.72 | 34,861,014.25 | 35,068,341.94 |
| 开发支出 | 12,996,001.75 | 12,787,729.61 | 18,592,084.23 | 18,041,723.41 |
| 长期待摊费用 | 1,145,817.19 | 1,310,699.47 | 1,571,230.92 | 1,879,586.97 |
| 递延所得税资产 | 10,273,510 | 9,484,918.36 | 7,820,445.9 | 6,103,101.44 |
| 其他非流动资产 | 22,989,809.84 | 25,655,746.14 | 121,422,751.74 | 91,550,246.41 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 956,799,051.16 | 929,693,757.79 | 876,642,940.21 | 832,682,764.22 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 1,664,893,442.81 | 1,647,900,520.96 | 1,528,053,413.91 | 1,462,350,006.46 |
| 流动负债: | | | | |
| 短期借款 | 192,642,050 | 200,157,720.37 | 173,680,785.95 | 137,581,830.35 |
| 应付票据及应付账款 | 115,770,122.06 | 130,417,700.86 | 101,980,356.31 | 87,907,090.2 |
| 其中：应付票据 | 40,944,172.15 | 51,652,578.6 | 33,270,090.38 | 10,591,705.92 |
| 应付账款 | 74,825,949.91 | 78,765,122.26 | 68,710,265.93 | 77,315,384.28 |
| 合同负债 | 26,481,093 | 26,888,436.26 | 20,588,178.06 | 19,404,037.3 |
| 应付职工薪酬 | 11,179,365.59 | 20,142,205.27 | 14,834,148.63 | 11,581,582.29 |
| 应交税费 | 10,392,306.38 | 3,360,909.48 | 10,134,759.13 | 3,767,600.72 |
| 其他应付款合计 | 57,773,011.76 | 61,688,240 | 58,577,660.13 | 62,184,756.75 |
| 一年内到期的非流动负债 | 167,085,632.62 | 100,230,728.3 | 87,386,953.09 | 101,565,452.71 |
| 其他流动负债 | 785,105.29 | 574,010.99 | 200,000 | 110,000 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 582,108,686.7 | 543,459,951.53 | 467,382,841.3 | 424,102,350.32 |
| 非流动负债: | | | | |
| 长期借款 | 96,939,801.51 | 182,030,162.93 | 137,862,093.07 | 151,265,426.4 |
| 租赁负债 | - | - | - | 154,166.34 |
| 递延收益 | 19,598,436.36 | 4,088,005.79 | 4,158,124.82 | 4,270,783.82 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 116,538,237.87 | 186,118,168.72 | 142,020,217.89 | 155,690,376.56 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 698,646,924.57 | 729,578,120.25 | 609,403,059.19 | 579,792,726.88 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 112,418,556 | 112,418,556 | 112,000,000 | 112,000,000 |
| 资本公积 | 390,374,812.81 | 389,591,430.29 | 383,357,305.59 | 382,361,933.55 |
| 盈余公积 | 18,702,580.42 | 18,702,580.42 | 12,140,127.85 | 12,140,127.85 |
| 未分配利润 | 444,750,569.01 | 397,630,868.79 | 411,116,239.21 | 375,957,224.42 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 966,246,518.24 | 918,343,435.5 | 918,613,672.65 | 882,459,285.82 |
| 少数股东权益 | - | -21,034.79 | 36,682.07 | 97,993.76 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 966,246,518.24 | 918,322,400.71 | 918,650,354.72 | 882,557,279.58 |
| 负债和股东权益合计 | 1,664,893,442.81 | 1,647,900,520.96 | 1,528,053,413.91 | 1,462,350,006.46 |
| 公告日期 | 2025-04-25 | 2025-04-25 | 2024-10-29 | 2024-07-31 |
| 审计意见(境内) | | 标准无保留意见 | | |